key: cord-0072528-988mfd9e
authors: Shi, Yanan; Chen, Mingqi; Zhao, Zehua; Pan, Juhua; Huang, Shijing
title: Network Pharmacology and Molecular Docking Analyses of Mechanisms Underlying Effects of the Cyperi Rhizoma-Chuanxiong Rhizoma Herb Pair on Depression
date: 2021-12-22
journal: Evid Based Complement Alternat Med
DOI: 10.1155/2021/5704578
sha: 80659171ade4da7faec1f3889e522f7401ac72bd
doc_id: 72528
cord_uid: 988mfd9e

OBJECTIVE: We aimed to investigate the mechanisms underlying the effects of the Cyperi Rhizoma-Chuanxiong Rhizoma herb pair (CCHP) against depression using a network pharmacology approach. METHODS: A network pharmacology approach, including screening of active compounds, target prediction, construction of a protein-protein interaction (PPI) network, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses, and molecular docking, molecular dynamics (MD) simulations, and molecular mechanics Poisson–Boltzmann surface area (MMPBSA), were used to explore the mechanisms of CCHP against depression. RESULTS: Twenty-six active compounds and 315 and 207 targets of CCHP and depression, respectively, were identified. The PPI network suggested that AKT1, IL-6, TP53, DRD2, MAPK1, NR3C1, TNF, etc., were core targets. GO enrichment analyses showed that positive regulation of transcription from RNA polymerase II promoter, plasma membrane, and protein binding were of great significance. Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, dopaminergic synapse, and mTOR signaling pathway were important pathways. Molecular docking results revealed good binding affinities for the core compounds and core targets. MD simulations and MMPBSA validated that quercetin can stably bind to 6hhi. CONCLUSIONS: The effects of CCHP against depression involve multiple components, targets, and pathways, and these findings will promote further research on and clinical application of CCHP.

Depression is a highly prevalent psychiatric illness with a global incidence of 258 million cases in 2017 and is predicted to be the leading contributor to worldwide disease burden by 2030, with a disability-adjusted life year (DALY) value of 84.32 million [1] [2] [3] . Depression has a major influence on individual health, is associated with high risks of lifetime suicide attempts, and imposes a heavy socioeconomic burden [1] . However, two-thirds of the patients prescribed antidepressant drugs do not show a beneficial treatment response [4] .

Many studies have reported that traditional Chinese medicine (TCM) can treat depression effectively with fewer adverse events [6] [7] [8] , since TCM treats depression from a holistic perspective with multiple ingredients and targets, rather than focusing on specific targets like other antidepressants [9] . Fewer adverse events of TCM also result from lower toxicities of herbs and further toxicity reduction by formulas, which are composed of interactive herbs [8] .

Herb pairs used in TCM are composed of two herbs with synergistic effects; herb pairs are of particular clinical significance and provide an important perspective in studies of herb compatibility [10] . e combination of Cyperi Rhizoma and Chuanxiong Rhizoma is deemed the Cyperi Rhizoma-Chuanxiong Rhizoma herb pair (CCHP) in TCM [11] . It is an important part of the famous formulas widely used in treating depression, including the Yueju pill from Danxi Xinfa and Chaihu Shugan San from Jingyue Quanshu. Both Yueju pill and Chaihu Shugan San were found to exert significant antidepressant effects in clinical trials [12] [13] [14] [15] . Yueju pill exerted antidepressant effects by regulating PKA/CREB, NMDA, and Akt/mTOR signaling [16] [17] [18] , while Chaihu Shugan San has been suggested to treat depression through BDNF signaling, gut microbiota, and other mechanisms [19, 20] . However, the compatible mechanisms underlying the therapeutic effects of CCHP require further research.

Network pharmacology is a new approach derived from systems biology, polypharmacology, network theory, and so on. TCM is characterized by holism, and TCM formulas are known to treat diseases by employing multiple ingredients and targets from a systematic perspective. Since the properties of network pharmacology are in accordance with the holistic philosophy of TCM, network pharmacology offers a new approach to innovating drug discovery and an effective tool for exploring TCM from a systematic perspective [21, 22] . e combination of TCM and network pharmacology can elucidate the underlying mechanisms at the molecular level and systematically illustrate complicated biological network relationships [22, 23] .

us, the purpose of this study was to investigate the multiple mechanisms of CCHP in treating depression using network pharmacology and molecular docking to provide insights into the research and therapy of depression. A detailed workflow is shown in Figure 1 .

e active compounds of CCHP were predominantly retrieved from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP, https://tcmspw. com/tcmsp.php). e core compounds of CCHP that were recorded in the literature and not included in TCMSP were also obtained. TCMSP can provide information on the ingredients, corresponding targets, and pharmacokinetic properties of TCM [24] . e database provides pharmacokinetic information, such as drug-likeness (DL) and oral bioavailability (OB). e screening thresholds of compounds retrieved from TCMSP were set as OB ≥ 30% and DL ≥ 0.18 [25] . Compounds without target information were removed.

We used TCMSP and the search tool for interacting chemicals (STITCH, http://stitch.embl.de/) to acquire the targets of each compound [25] . In STITCH, we selected "Homo sapiens" as the species and chose targets with a combined score of ≥0.7.

e targets of the compounds obtained were standardized in the UniProt (https://www.uniprot.org) database, and "reviewed" and "human" UniProtKB was selected [26] . en, the duplicated targets were removed from the targets obtained.

To illustrate the relationships between herbs, compounds, and targets of CCHP, Cytoscape 3.2.1 Software (http://www.cytoscape.org/) [27] was utilized to build a herb-compound-target network.

Targets related to depression were retrieved from the therapeutic target database (TTD, https://db.idrblab.org/ttd/) [28] , DrugBank (https://www.drugbank.ca/) [29] , and GeneCards Version 5.1 (https://www.genecards.org/) [30] databases with the keyword "Depression." In GeneCards, targets with a score of ≥16 were screened.

To obtain the targets of CCHP in treating depression, the predicted targets of the compounds of CCHP were intersected with targets related to depression, and a Venn diagram was obtained using the Venny 2.1 (http://bioinfogp. cnb.csic.es/tools/venny/index.html) mapping tool.

Core Target Screening. To illuminate the interactions among proteins, the targets of CCHP in treating depression were input into STRING 11.0 (https://string-db.org/) for proteinprotein interaction (PPI) analysis [31] . e parameters were set as follows: "Homo sapiens" was chosen as the species, and a combined score >0.9 was used as the threshold. e results for the PNG and TSV formats were exported. e PPI network was visualized by Cytoscape 3.2.1 and analyzed using the "Network analyzer" plug-in, which is a tool of Cytoscape. e screening thresholds were the median values of the degrees of all nodes.

e Database for Annotation, Visualization, and Integrated Discovery (DA-VID) v6.8 (https://david.ncifcrf.gov/) [32, 33] was utilized for gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment to illuminate the biological function and enriched pathways of targets of CCHP in treating depression, with a screening criterion of p < 0.01 and false discovery rate (FDR) <0.05.

Based on KEGG analysis, Cytoscape was employed to construct a target-pathway network of the top 20 key signaling pathways and the enriched targets. e relationships between pathways and enriched targets are shown in the network. e network nodes are the pathways and enriched targets, and the size of the nodes represents the topological importance of the nodes.

e nodes with the top six degrees of the herb-compound-target network and PPI network were chosen as core compounds and targets for molecular docking. First, the 2D structures of the core compounds were acquired from the PubChem database (https:// pubchem.ncbi.nlm.nih.gov/) [34] and input into the ChemBio 3D Software to export the 3D structures. Auto-DockTools 1.5.6 Software was then employed to add charge values and export the structures in pdbqt format. Second, the 3D structures of the core targets were acquired from the RCSB PDB database (https://www.rcsb.org/) [35] and deleted water and other ligands. AutoDockTools 1.5.6 was used to add hydrogen and charges and convert the structures into pdbqt format. Finally, AutoDock Vina 1.1.2 was utilized to perform molecular docking and analyze the results [36] . Docking results were visualized and analyzed using PyMOL 1.7.2.1 and Ligplus 2.2.4. e docking of core compounds and targets with lower docking energies had stronger binding forces.

Since AKT1 (PDB ID: 6hhi) was the core target and quercetin was the core compound, the docking conformation of 6hhi and quercetin, which had low binding energy, was selected as the initial conformation for molecular dynamics (MD) simulations. G4N, the primitive ligand of 6hhi, was used as the positive control. MD simulations were performed using the GROMACS 2018.4 program [37] under constant temperature and pressure and periodic boundary conditions. Amber99 SB all-atom force field and TIP3P water model were applied [38] . During MD simulations, all bonds involving hydrogen atoms were constrained using the LINear Constraint Solver (LINCS) algorithm [39] with an integration step of 2 fs. Electrostatic interactions were calculated using the particle mesh Ewald (PME) method [40] . e nonbonded interaction cutoff was set to 10Å and updated every 10 steps. e V-rescale temperature coupling method [41] was used to control the simulation temperature at 300 K, and the Parrinello-Rahman method [42] was used to control the pressure at 1 bar. Evidence-Based Complementary and Alternative Medicine First, energy minimization was performed in the two systems using 5000 steps of steepest descent algorithm with the convergence of energy minimization of 100 kJ/mol/nm to eliminate excessive interatomic contact. en, the systems were heated gradually from 0 to 300 K in the canonical ensemble (NVT) and equilibrated at 300 K for 1000 ps in the constant pressure-constant temperature ensemble (NPT). Finally, the systems were subjected to MD simulations for 50 ns and the conformation was preserved every 10 ps. e simulation results were visualized using the GROMACS embedding program and visual molecular dynamics (VMD).

e molecular mechanics Poisson-Boltzmann surface area (MMPBSA) method [43] was used to calculate the binding energy between substrate small molecules and proteins in the two protein systems.

A total of 26 compounds of CCHP were acquired from TCMSP and the literature.

Among the compounds, 18 were from Cyperi Rhizoma and 9 were from Chuanxiong Rhizoma. e details of the compounds in each herb are shown in Table 1 . By searching TCMSP and STITCH, 315 targets of the CCHP compounds were acquired, which included 302 targets of Cyperi Rhizoma and 73 targets of Chuanxiong Rhizoma. Cyperi Rhizoma and Chuanxiong Rhizoma shared 59 targets that may mediate their synergistic effects.

Network.

e herb-compound-target network ( Figure 2 ) built by Cytoscape contained 343 nodes and 762 edges. A Cytoscape network analyzer was used to perform topological analysis of the network. In the network, the degree represents the number of nodes that are directly connected to one node. erefore, nodes with larger degrees may be key compounds or targets that play important roles in the network and were screened and further analyzed. As shown in the network, one compound may act on many targets, and numerous compounds may correspond to the same target. Considering the degrees of the compounds, MOL000098 (quercetin), MOL000006 (luteolin), MOL000422 (kaempferol), MOL000358 (beta-sitosterol), and MOL000354 (isorhamnetin) are pivotal compounds.

We retrieved 207 targets related to depression from the TTD, DrugBank, and GeneCards databases (Additional File 1: Table S1 ). e targets of CCHP were intersected with targets related to depression to obtain the targets of CCHP in treating depression, and 40 overlapping targets were obtained using this approach (Table 2, Additional File 2: Figure S1 ).

e STRING database was utilized to analyze the interactions of these overlapping targets and construct the PPI diagram ( Figure 3 (a)) with an average node degree of 12.8 and a PPI enrichment p value of <1.0e − 16.

Targets with a combined score >0.9 were screened and input into Cytoscape to visualize and analyze the PPI network ( Figure 3(b) ). Topological analysis of the PPI network was performed using the Cytoscape Network Analyzer. e network included 32 nodes and 57 edges. e screening criteria for core targets were the median values of degree. e core targets obtained were AKT1, IL-6, TP53, DRD2, MAPK1, NR3C1, TNF, ESR1, SST, OPRM1, DRD3, ADRA2A, and ADRA2C. e top 16 entries in CC analysis included the plasma membrane, cytoplasm, integral component of the plasma membrane, and the extracellular region (Figure 4(b) ). In MF analysis, protein binding was the term that targets were predominantly enriched in Figure 4 (c).

Analyses. KEGG pathway enrichment analyses were performed using the DAVID with the screening criterion of p < 0.01, and 51 pathways were obtained. e top 20 significantly enriched pathways included neuroactive ligand-receptor interaction (hsa04080), PI3K-Akt signaling pathway (hsa04151), pathways in cancer (hsa05200), dopaminergic synapse (hsa04728), and mTOR signaling pathway (hsa04150). e top 20 enriched pathways are displayed in detail in Figure 5 .

We input the top 20 key pathways and the enriched targets into Cytoscape to construct and analyze the target-pathway network ( Figure 6 ). e degree was selected to assess the importance of the nodes. AKT1, MAPK1, GSK3B, TNF, MTOR, and PTEN had larger degrees and were core targets enriched in these pathways in the network. Neuroactive ligand-receptor interaction (hsa04080), pathways in cancer (hsa05200), and the PI3K-Akt signaling pathway (hsa04151) had larger degrees than other pathways.

Molecular docking aims to predict the interactions between proteins and small molecules. e core compounds were quercetin, luteolin, kaempferol, beta-sitosterol, isorhamnetin, and stigmasterol. e core targets were AKT1 (PDB ID: 6hhi) [44] , IL-6 (PDB ID: 1alu) [45] , TP53 (PDB ID: 6gga) [46] , DRD2 (PDB ID: 6cm4) [47] , MAPK1 (PDB ID: 6slg) [48] , and NR3C1 (PDB ID: 6dxk) [49] . As shown in Table 3 , the binding energy values of the core compounds in CCHP with the core targets are less than −5 kcal/mol, indicating strong affinity. A lower binding energy indicates a stronger binding force. As shown in Figure 7 , the core compounds are strongly bound to the core targets by forming hydrophobic and polar interactions.

Root-mean-square deviation (RMSD) indicates the sum of all atomic deviations between the conformation at a certain time and the target conformation, which is an important basis for measuring the stability of the system. e system of the binding complex of 6hhi and its primitive ligand G4N was named 6hhi_G4N, and the system of the binding complex of 6hhi and quercetin was named 6hhi_Quercetin. Figure 8 shows that the RMSD values of all Cα atoms in the 6hhi_G4N and 6hhi_Quercetin systems change with time. e two systems basically tended to be stable after 10 ns, with the mean RMSD values of 0.194 ± 0.026 nm and 0.228 ± 0.027 nm, respectively. e RMSD fluctuations of both systems are small. In particular, the RMSD values of the 6hhi_Quercetin system are significantly higher than those of the 6hhi_G4N system from 5 ns, which may be due to the differences in small molecule compounds bound in the 6hhi protein that affect the stability of the entire complex to some extent.

Root-mean-square fluctuations (RMSFs) can indicate the flexibility of amino acid residues in proteins. e amino acid flexibility distribution of 6hhi_G4N and 6hhi_Quercetin is shown in Figure 9 . After the binding of quercetin, the flexibility of most amino acids of the 6hhi shows a significant increase (ΔRMSF > 0). e above results show that the RMSF of most amino acids of 6hhi increases slightly after the binding of quercetin compared with the previous 6hhi_G4N system. e increase in RMSF may be due to the differences in the key amino acids of the interactions between the two molecules.

e results of MMPBSA show that the binding energy of the substrate and protein in 6hhi_G4N (binding energy � −125.522 ± 14.620 kJ/mol) is higher than that in 6hhi_-Quercetin (binding energy � −103.144 ± 10.692 kJ/mol) ( Table 4 ). e results showed that both quercetin and G4N could stably bind to the active pocket of 6hhi, and G4N had stronger interactions with 6hhi than quercetin.

Depression, as a highly prevalent psychiatric illness, has serious effects on physical and mental health and can even lead to suicide [50] . Although some antidepressants are effective, they often cause adverse effects and are expensive [5] . Chinese herbal medicine has been proven to be effective in treating depression through multiple components, targets, and pathways [8] . CCHP is the core component of many famous formulas that have significant curative effects on depression. We employed a network pharmacology approach to investigating the multiple mechanisms of CCHP in treating depression. We obtained compounds and corresponding targets from the TCMSP and STITCH databases. Sitosterol was a common compound in Cyperi Rhizoma and Chuanxiong Rhizoma. Quercetin, a flavonoid, is present in numerous plants and exerts antidepressant effects by regulating the signaling related to BDNF [51, 52] , alleviating oxidative stress and neuroinflammation [53] , and inhibiting astrocyte reactivation [54] . Similarly, luteolin is a flavonoid with various biological properties [55] . e mechanisms underlying the antidepressant-like effect of luteolin may include the inhibition of endoplasmic reticulum stress [55, 56] and the regulation of monoaminergic and cholinergic functions [57] . e herb-compound-target network ( Figure 2 ) showed that the relationships between the compounds and their corresponding targets were complicated. Quercetin, luteolin, kaempferol, beta-sitosterol, and isorhamnetin had larger degrees than other compounds, and they were core compounds in the network. One compound can act on several targets, and numerous compounds may share a common target. erefore, we can infer that multiple compounds of CCHP may act on depression through multiple targets. Nodes represent targets, and edges stand for the interactions between the targets. In Figure 3 (b), with an increase in the degrees, the colors of the nodes change from yellow to red, and the sizes of the nodes increase.

Targets of depression were retrieved from the TTD, DrugBank, and GeneCards databases; the targets of depression and CCHP were intersected; 40 targets were identified as targets of CCHP in treating depression (Additional File 2: Figure S1 ). e targets of CCHP in the treatment of depression showed numerous interactions. e PPI network of CCHP in treating depression (Figure 3(b) ), which was visualized and analyzed using Cytoscape, illustrated that AKT1, IL-6, TP53, DRD2, MAPK1, NR3C1, TNF, ESR1, SST, OPRM1, DRD3, ADRA2A, and ADRA2C were core targets of CCHP in treating depression. AKT1, an isoform of the serine/threonine kinase [58] , is involved in monoamine neurotransmission and plasticity [59, 60] . A reduction in the kinase activity of AKT1 is related to depression [61] . AKT1 gene polymorphisms may be a sign of depression severity and treatment response [58, 62, 63] . Crosstalk between inflammation and neurocircuits may be related to the pathogenesis and treatment response of depression [64] . IL-6 is a cytokine that is significantly associated with depression [65] . An increase in IL-6 levels has been observed in both the acute and chronic stages of depression [66] . IL-6 levels were significantly elevated via pivotal inflammatory signaling in response to stressors [67, 68] . TP53, which is called the Evidence-Based Complementary and Alternative Medicine mammalian cell "gatekeeper," is a pro-apoptotic factor [69, 70] that plays a critical role in regulating astrocytic autophagy and neuronal apoptosis, which may explain the mechanisms underlying the antidepressant effects of fluoxetine [70, 71 ]. e dopaminergic system may be related to the pathogenesis of depression and the response to antidepressants [72] . DRD2 is a pivotal protein in the dopaminergic system [73] . e vulnerability to depression and reactivity of antidepressants are associated with DRD2 gene polymorphisms [73] [74] [75] . MAPK1, which is involved in regulating neuroplasticity and inflammatory processes, appears to reflect vulnerability to depression [76, 77] . MAPK1 polymorphisms may be related to the remission of antidepressant treatment [77] . e results of GO analysis are shown in Figure 4 . BP analysis (Figure 4(a) ) indicated that targets related to the regulation of transcription and gene expression, response to drug, signal transduction, positive regulation of nitric oxide biosynthetic process, and the regulation of cell proliferation were largely enriched. CC terms (Figure 4(b) ) were mostly related to the plasma membrane, cytoplasm, extracellular region, and cytosol. MF terms (Figure 4 (c)) were primarily related to protein binding.

As shown in Figure 5 , neuroactive ligand-receptor interaction (hsa04080), PI3K-Akt signaling pathway (hsa04151), dopaminergic synapse (hsa04728), mTOR signaling pathway (hsa04150), and HIF-1 signaling pathway (hsa04066), which enriched many targets, may contribute to e meaning of the items on the 2D interaction diagrams is as follows Ligand bond Non-ligand bond 3.0 Hydrogen bond and Non-ligand residues involved His 53 in hydrophobic contact (s) Corresponding atoms involved in hydrophobic contact (s) its length Evidence-Based Complementary and Alternative Medicine the antidepressant effects of CCHP. Neuroactive ligandreceptor interaction signaling contributes to the transmission of extracellular signals into cells [78] . is pathway, which includes numerous receptors and ligands, is linked to the mechanism of depression and the antidepressant effects of many TCM formulas [78] [79] [80] [81] [82] . PI3K/Akt signaling, which is activated by neuroinflammation, leads to neuroplastic damage in depression [83] . PI3K/Akt signaling may regulate neuroinflammatory factors and neurotrophins and exert antidepressant effects [84] . Inhibition of PI3K/Akt signaling plays a role in the neuroprotective effects of fluoxetine [85] . BDNF/TrkB activates PI3K/Akt signaling during antidepressant action [86] . e depletion of monoamine neurotransmitters is the pathophysiological basis of depression [87] . Decreased dopaminergic transmission may contribute to blunted reward processing and repaired reward learning, which are features of depression [88] [89] [90] . e antidepressant effects of dopamine agonists may depend on the ventrostriatal dopamine and reward function [91] . mTOR signaling, as a downstream intracellular signal, is associated with antidepressant effects [92, 93] . Fast-acting antidepressants, such as ketamine, enhance mTOR function and improve neurogenesis and plasticity [94, 95] . HIF-1 mediates mitochondrial metabolism, reduces oxidative stress, and plays a role in energy supply in depression [96] [97] [98] . Upregulation of HIF-1 may provide a new approach to antidepressant treatment [96] . e target-pathway network illustrated that AKT1, MAPK1, GSK3B, TNF, MTOR, and PTEN were core targets enriched in key signaling pathways that played crucial roles in the treatment of depression by CCHP. GSK3B may be involved in the development of depression by inhibiting Erk-CREB-BDNF signaling [99] , and PI3K/Akt/mTOR/ GSK3B signaling may be the mechanism underlying the rapid antidepressant effects [100] . TNF polymorphisms are associated with depression [65] , and the suppression of TNF-α/TNFR1/NF-κB signaling alleviated neuroinflammation and depression [101] .

Molecular docking was employed to validate the interactions between the core compounds of CCHP and the core targets, and affinity analyses were used to estimate the binding energy of a ligand and the intensity of the interactions. e results indicated that multiple core compounds of CCHP could bind to multiple core targets, and this may be the basis of the mechanism underlying the therapeutic effects of CCHP.

MD simulations are able to predict the motion of each atom over time and refine the conformation of the receptorligand complex [102] [103] [104] . MD simulation in combination with binding free energy calculation can make the binding free energy estimates precise and re-rank the candidates [105] . MD simulation and MMPBSA results showed that quercetin can stably bind to the active pocket of 6hhi.

Nevertheless, this study had some limitations. e compound and target information used in the evaluations was mainly obtained from databases; however, some bioactive ingredients and targets may not be included in the databases. e inhibitory and activated effects of the targets are difficult to differentiate. e ingredients obtained from the databases may be distinct from those absorbed and utilized in the patient's body. Moreover, potential complex interactions between the ingredients were not taken into consideration. Accordingly, further experimental verification of the multiple mechanisms of CCHP in treating depression both in vivo and in vitro is required to validate the obtained results.

In this study, quercetin, luteolin, kaempferol, beta-sitosterol, and isorhamnetin were the core compounds of CCHP in treating depression. CCHP treated depression by acting on multiple key targets, such as AKT1, IL-6, TP53, DRD2, MAPK1, NR3C1, TNF, ESR1, SST, OPRM1, DRD3, ADRA2A, and ADRA2C, and through important biological processes, such as positive regulation of transcription from RNA polymerase II promoter, plasma membrane, and protein binding. CCHP exerted antidepressant effects by regulating multiple key signaling pathways such as neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, dopaminergic synapse, and mTOR signaling pathway. AKT1, MAPK1, GSK3B, TNF, MTOR, and PTEN were the core targets enriched in key signaling pathways. CCHP treats depression through multiple components, targets, and pathways. However, the specific antidepressant effects of CCHP require experimental verification. Nitric oxide synthase, brain NR3C2:

Mineralocorticoid receptor SLC6A4: Sodium-dependent serotonin transporter CHRNA2: Neuronal acetylcholine receptor subunit alpha-2 COL1A1: Collagen alpha-1(I) chain CYP2B6: Cytochrome P450 2B6 DRD1: D(1A) dopamine receptor GABRA1: Gamma-aminobutyric acid receptor subunit alpha-1 GRIA2:

Glutamate receptor 2 HTR3A: 5-Hydroxytryptamine receptor 3A SLC6A2: Sodium-dependent noradrenaline transporter HIF-1:

Hypoxia-inducible factor-1 TrkB:

Tropomyosin-related kinase B Erk:

Extracellular signal-regulated kinase TNFR1:

Tumor necrosis factor receptor 1 NF-κB:

Nuclear factor-κB BP:

Biological process CC: Cellular component MF:

Molecular function PI3K:

Phosphatidylinositol 3-kinase MD:

Molecular dynamics LINCS:

LINear Constraint Solver PME:

Particle mesh Ewald NVT:

Canonical ensemble NPT:

Constant pressure-constant temperature ensemble VMD:

Visual molecular dynamics MMPBSA: Molecular mechanics Poisson-Boltzmann surface area RMSD:

Root-mean-square deviation RMSFs:

Root-mean-square fluctuations.

Data Availability e datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

e authors declare that they have no conflicts of interest.

Depression

Changes in the global burden of depression from 1990 to 2017: findings from the global burden of disease study

Research on the pathological mechanism and drug treatment mechanism of depression

Tricyclic antidepressant poisoning: cardiovascular toxicity

A systematic review on the efficacy, safety and types of Chinese herbal medicine for depression

Efficacy and safety of Chinese herbal medicine for depression: a systematic review and meta-analysis of randomized controlled trials

Chinese herbal medicine for the treatment of depression: applications, efficacies and mechanisms

Traditional Chinese medicine in depression treatment: from molecules to systems

Compatibility art of traditional Chinese medicine: from the perspective of herb pairs

Hyphenated chromatography detection and compound-target-disease investigation on herb-pair Chuanxiong Rhizoma-xiangfu Rhizoma

A role of Yueju in fast-onset antidepressant action on major depressive disorder and serum BDNF expression: a randomly double-blind, fluoxetine-adjunct, placebo-controlled, pilot clinical study

Yueju pill in the treatment of depression combining TCM syndrome and disease:A randomized double-blind controlled trial

Meta-analysis of the clinical effectiveness of traditional Chinese medicine formula Chaihu-Shugan-San in depression

Changes in regional cerebral blood flow with Chaihu-Shugan-San in the treatment of major depression

PKA-CREB-BDNF signaling regulated long lasting antidepressant activities of Yueju but not ketamine

Yueju pill rapidly induces antidepressant-like effects and acutely enhances BDNF expression in mouse brain

Instant and lasting downregulation of NR1 expression in the Hippocampus is associated temporally with antidepressant activity after acute Yueju

Antidepressant-like effects and cognitive enhancement of coadministration of Chaihu shugan san and fluoxetine: dependent on the BDNF-ERK-CREB signaling pathway in the Hippocampus and frontal cortex

Gut microbiota is the key to the antidepressant effect of chaihu-shu-Gan-san

Network pharmacology: the next paradigm in drug discovery

Traditional Chinese medicine network pharmacology: theory, methodology and application

Network pharmacologybased dissection of the anti-diabetic mechanism of Lobelia chinensis

Systems pharmacology dissection of multi-scale mechanisms of action of huo-14 Evidence-Based Complementary and Alternative Medicine Xiang-Zheng-Qi formula for the treatment of gastrointestinal diseases

Mechanism of Dayuanyin in the treatment of coronavirus disease 2019 based on network pharmacology and molecular docking

UniProt: e universal protein knowledgebase in 2021

Cytoscape: a software environment for integrated models of biomolecular interaction networks

erapeutic target database update 2018: enriched resource for facilitating bench-toclinic research of targeted therapeutics

DrugBank 5.0: a major update to the DrugBank database for 2018

e GeneCards suite: from gene data mining to disease genome sequence analyses

STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists

PubChem in 2021: new data content and improved web interfaces

e protein Data Bank

AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

GROMACS: fast, flexible, and free

Comparison of simple potential functions for simulating liquid water

LINCS: a linear constraint solver for molecular simulations

Particle mesh Ewaldan N.log(N) method for Ewald sums in large systems

Molecular dynamics with coupling to an external bath

Predicting crystal structures: the Parrinello-Rahman method revisited

g_mmpbsa-a GRO-MACS tool for high-throughput MM-PBSA calculations

Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt

1.9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling

A structureguided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C

Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone

Discovery of a potent and selective oral inhibitor of ERK1/2 (AZD0364) that is efficacious in both monotherapy and combination therapy in models of nonsmall cell lung cancer (NSCLC)

Discovery of a potent and selective steroidal glucocorticoid receptor antagonist (ORIC-101)

Burden of depression in China, 1990-2017: findings from the global burden of disease study 2017

Quercetin exerts antidepressant and cardioprotective effects in estrogen receptor α-deficient female mice via BDNF-AKT/ERK1/2 signaling

Quercetin alleviates LPSinduced depression-like behavior in rats via regulating BDNF-related imbalance of copine 6 and TREM1/2 in the Hippocampus and PFC

Quercetin prevents chronic unpredictable stress induced behavioral dysfunction in mice by alleviating hippocampal oxidative and inflammatory stress

Dietary quercetin attenuates depressive-like behaviors by inhibiting astrocyte reactivation in response to stress

An update of palmitoylethanolamide and luteolin effects in preclinical and Evidence-Based Complementary and Alternative Medicine 15

clinical studies of neuroinflammatory events

Luteolin shows an antidepressant-like effect via suppressing endoplasmic reticulum stress

Rosmarinus officinalis polyphenols produce anti-depressant like effect through monoaminergic and cholinergic functions modulation

An association of AKT1 gene polymorphism with antidepressant treatment response

A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health

Decreased AKT1/mTOR pathway mRNA expression in short-term bipolar disorder

Alterations in phosphatidylinositol 3-kinase activity and PTEN phosphatase in the prefrontal cortex of depressed suicide victims

Association between AKT1 gene polymorphisms and depressive symptoms in the Chinese Han population with major depressive disorder

Genetic variant of AKT1 and AKTIP associated with late-onset depression in a Brazilian population

e role of inflammation in depression: from evolutionary imperative to modern treatment target

Genetic contributions of inflammation to depression

A metaanalysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression

Increased stressinduced inflammatory responses in male patients with major depression and increased early life stress

A mechanism converting psychosocial stress into mononuclear cell activation

e role of tumor suppressor p53 in metabolism and energy regulation, and its implication in cancer and lifestyle-related diseases

p53 and mitochondrial function in neurons

e effect of fluoxetine on astrocyte autophagy flux and injured mitochondria clearance in a mouse model of depression

Striatal dopamine D2/3 receptor-mediated neurotransmission in major depression: implications for anhedonia, anxiety and treatment response

Functional tag SNPs inside the DRD2 gene as a genetic risk factor for major depressive disorder in the Chinese Han population

DRD2/ ANKK1 Taq1A polymorphism (rs1800497) has opposing effects on D2/3 receptor binding in healthy controls and patients with major depressive disorder

e DRD2 rs1800497 polymorphism increase the risk of mood disorder: evidence from an update meta-analysis

Genes involved in neurodevelopment, neuroplasticity and major depression: No association for CACNA1C, CHRNA7 and MAPK1

Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients

Characterization of the drugged human genome

Prioritization and comprehensive analysis of genes related to major depressive disorder

Metabolomic analysis of the hippocampus in a rat model of chronic mild unpredictable stress-induced depression based on a pathway crosstalk and network module approach

Mechanism of Chaihu shugan powder () for treating depression based on network pharmacology

Network pharmacology-based research of active components of albiziae flos and mechanisms of its antidepressant effect

PI3K/AKT/ GSK3β/CRMP-2-mediated neuroplasticity in depression induced by stress

Isorhynchophylline exerts antidepressant-like effects in mice via modulating neuroinflammation and neurotrophins: involvement of the PI3K/ Akt/GSK-3β signaling pathway

Involvement of PI3K/Akt/ FoxO3a and PKA/CREB signaling pathways in the protective effect of fluoxetine against corticosterone-induced cytotoxicity in PC12 cells

BDNF/NF-κB signaling in the neurobiology of depression

Depression: the case for a monoamine deficiency

e role of dopamine in the pathophysiology of depression

e mesolimbic dopamine reward circuit in depression

Dysfunctional reward processing in depression

Baseline reward processing and ventrostriatal dopamine function are associated with pramipexole response in depression

New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs

Iridoids from Gardeniae fructus ameliorates depression by enhancing synaptic plasticity via AMPA receptor-mTOR signaling

Rapid acting antidepressants in the mTOR pathway: current evidence

Crosstalk between inflammation and glutamate system in depression: signaling pathway and molecular biomarkers for ketamine's antidepressant effect

Elevating the level of hypoxia inducible factor may be a new potential target for the treatment of depression

e alteration of hypoxia inducible factor-1 (HIF-1) and its target genes in mood disorder patients

Potential antidepressant and resilience mechanism revealed by metabolomic study on peripheral blood mononuclear cells of stress resilient rats

Gsk3β aggravates the depression symptoms in chronic stress mouse model

e involvement of PI3K/Akt/mTOR/GSK3β signaling pathways in the antidepressant-like effect of AZD6765

Arctigenin protects against depression by inhibiting microglial activation and neuroinflammation via HMGB1/TLR4/NF-κB and TNFα/TNFR1/NF-κB pathways

Molecular dynamics simulation for all

Bringing molecular dynamics simulation data into view

Molecular dynamics simulations and novel drug discovery

e MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities

is work was funded by the National Natural Science Foundation of China (no. 81573790).

Additional File 1: Table S1 : targets related to depression. Additional File 2: Fig. S1 : Venn diagram of targets of CCHP and depression. (Supplementary Materials) 

YS conceived and designed the study. YS, MC, and ZZ collected the data. YS performed the data analysis. YS drafted the manuscript. SH supervised the study. SH and JP revised the manuscript All the authors read and approved the final manuscript.